LFCR

Lifecore Biomedical's stock price has been volatile in the past six months. Shares plunged over 33% following the Q4 2025 earnings report due to delayed volume expectations from key customers. Q1 2026 financial results showed a 34% year-over-year revenue decline and a net loss, leading to a moderate negative market reaction. Despite declines, Lifecore reaffirmed its 2026 revenue and adjusted EBITDA guidance and signed three new commercial site transfer programs in Q1 2026. Over the last year, LFCR shares have hit a 52-week high of $8.98 and a 52-week low of $3.63.